帕利哌酮合并阿立哌唑治疗难治性精神分裂症的疗效评估  

The efficacy of paricalcitol combined with aripiprazole in the treatment of refractory schizophrenia

作　　者：敖登格日勒 Aodenggerile(Inner Mongolia Mental Health Center,Hohhot,The Inner Mongolia Autonomous Region 010010,China)

机构地区：[1]内蒙古精神卫生中心精神三科,内蒙古自治区呼和浩特010010

出　　处：《安徽医药》2018年第10期2005-2008,共4页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探讨帕利哌酮合并阿立哌唑治疗难治性精神分裂症的疗效。方法收集2010年5月至2013年5月在内蒙古精神卫生中心住院的难治性精神分裂症患者60例,采用随机数字表法分为对照组(单一帕利哌酮组)30例及研究组(合用阿立哌唑组)30例。治疗前及治疗后第4、8周末采用PANSS评定临床疗效。采用不良反应量表(TESS)评定药物不良反应。结果两组患者在治疗第4周、第8周后的PANSS评分均有显著降低,但两组间比较差异无统计学意义(P>0.05);对照组的治疗有效率90.00%,研究组的治疗有效率93.33%,两者比较差异无统计学意义(χ~2=0.000,P=1.000);合用阿立哌唑组的溢乳、静坐不能、闭经、体质量增加等不良反应明显少于对照组,两组比较均差异有统计学意义(P<0.05)。结论帕利哌酮联合小剂量阿立哌唑治疗难治性精神分裂症疗效及耐受性均好,溢乳、静坐不能、闭经、体质量增加等不良反应的发生率较低,兼具疗效和安全性。Objective To investigate the therapeutic effeCT of paricalcitol combined with aripiprazole in the treatment of refraCTory schizophrenia. Methods A total of 60 patients with refraCTory schizophrenia hospitalized in Inner Mongolia Mental Health Center from May2010 to May 2013 were randomly assigned into control group（ n = 30,paricalcitol group） and study group（ n = 30,paricalcitol plus aripiprazole group）. The clinical efficacy was evaluated by PANSS before treatment and 4 and 8 weeks after treatment. Adverse drug reaCTions were evaluated by TESS. Results The PANSS scores of the two groups at the fourth week and eighth week after treatment were significantly lower,but there was no significant difference between the two groups（ P〉0. 05）. The effeCTive rate of treatment of paricalcitol group was 90% and the effeCTive rate of treatment of paricalcitol plus aripiprazole group was 93. 33%（ χ~2= 0. 000,P = 1. 000）.Adverse reaCTions in paricalcitol plus aripiprazole group,including galaCTorrhea,akathisia,amenorrhea,and weight gain,were significantly fewer than the control group; the difference between the two groups was statistically significant（ P〈0. 05）. Conclusions Paricalcitol combined with aripiprazole showed good efficacy and tolerance in the treatment of refraCTory schizophrenia; it is effeCTive and safe with lower incidence of adverse reaCTions.

关 键 词：精神分裂症 帕利哌酮 阿立哌唑 乳溢 体重增长 

分 类 号：R749.3[医药卫生—神经病学与精神病学]